ES2192877T3 - 4-alquenil (y alquinil) oxindoles como inhibidores de kinasas ciclina-dependientes, en particular cdk2. - Google Patents

4-alquenil (y alquinil) oxindoles como inhibidores de kinasas ciclina-dependientes, en particular cdk2.

Info

Publication number
ES2192877T3
ES2192877T3 ES99963422T ES99963422T ES2192877T3 ES 2192877 T3 ES2192877 T3 ES 2192877T3 ES 99963422 T ES99963422 T ES 99963422T ES 99963422 T ES99963422 T ES 99963422T ES 2192877 T3 ES2192877 T3 ES 2192877T3
Authority
ES
Spain
Prior art keywords
compounds
treatment
dependent kinases
control
oxindols
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99963422T
Other languages
English (en)
Inventor
Yi Chen
Wendy Lea Corbett
Apostolos Dermatakis
Jin-Jun Liu
Kin-Chun Luk
Paige E Mahaney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2192877T3 publication Critical patent/ES2192877T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención está dirigida a nuevos 4-alquenil y 4-alquinil oxindoles los cuales inhiben las quinasas dependientes de ciclina (CDKs) en particular CDK2, Estos compuestos y sus sales farmacéuticamente aceptables, y los profármacos de dichos compuestos, son agentes antiproliferativos útiles en el tratamiento o control de los desórdenes proliferativos celulares, en particular, del cáncer. La invención está también dirigida a las composiciones farmacéuticas conteniendo tales compuestos, y al uso de estos compuestos en la preparación de medicamentos para el tratamiento y/o prevención del cáncer, particularmente para el tratamiento o control de tumores sólidos. Los compuestos de la invención son especialmente útiles en el tratamiento o control de los tumores de colon y mama.
ES99963422T 1998-12-17 1999-12-08 4-alquenil (y alquinil) oxindoles como inhibidores de kinasas ciclina-dependientes, en particular cdk2. Expired - Lifetime ES2192877T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11259198P 1998-12-17 1998-12-17
US14907399P 1999-08-16 1999-08-16

Publications (1)

Publication Number Publication Date
ES2192877T3 true ES2192877T3 (es) 2003-10-16

Family

ID=26810131

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99963422T Expired - Lifetime ES2192877T3 (es) 1998-12-17 1999-12-08 4-alquenil (y alquinil) oxindoles como inhibidores de kinasas ciclina-dependientes, en particular cdk2.

Country Status (20)

Country Link
US (3) US6130239A (es)
EP (1) EP1157019B1 (es)
JP (1) JP2002532492A (es)
KR (1) KR100649925B1 (es)
CN (1) CN1138773C (es)
AR (1) AR024847A1 (es)
AT (1) ATE234830T1 (es)
AU (1) AU770375B2 (es)
BR (1) BR9916327A (es)
CA (1) CA2354873A1 (es)
CO (1) CO5261600A1 (es)
DE (1) DE69906152T2 (es)
DK (1) DK1157019T3 (es)
ES (1) ES2192877T3 (es)
PE (1) PE20001537A1 (es)
PT (1) PT1157019E (es)
TR (1) TR200101860T2 (es)
TW (1) TW550262B (es)
UY (1) UY25857A1 (es)
WO (1) WO2000035908A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
DK1157019T3 (da) * 1998-12-17 2003-07-14 Hoffmann La Roche 4-alkenyl- (og alkynyl-)oxindoler som inhibitorer af cyklinafhængige kinaser, især CDK2
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
AU1928501A (en) * 1999-11-24 2001-06-04 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
WO2001045689A2 (en) * 1999-12-22 2001-06-28 Sugen, Inc. Indolinone derivatives for modulation of c-kit tyrosine protein kinase
DE122010000004I1 (de) * 2000-02-15 2010-04-15 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
WO2001072708A2 (en) * 2000-03-24 2001-10-04 Cor Therapeutics, Inc. OXINDOLE INHIBITORS OF FACTOR Xa
MY128449A (en) 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
EP1294688A2 (en) 2000-06-02 2003-03-26 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
JP2004502686A (ja) * 2000-06-30 2004-01-29 スージェン・インコーポレーテッド ４−ヘテロアリール−３−ヘテロアリーリデニル−２−インドリノンおよび蛋白質キナーゼ阻害剤としてのその使用
JP2004518669A (ja) * 2000-12-20 2004-06-24 スージェン・インコーポレーテッド ４−アリール置換インドリノン
US6504034B2 (en) 2001-01-23 2003-01-07 Hoffmann-La Roche Inc. Naphthostyrils
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
FR2822155B1 (fr) * 2001-03-13 2003-12-12 Aventis Pharma Sa Composes derives des oxindoles et leur application therapeutique en cancerologie
CA2455050C (en) * 2001-08-15 2007-02-20 Pharmacia & Upjohn Company Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
EP1434774A1 (en) 2001-10-10 2004-07-07 Sugen, Inc. 3-(4-substituted heterocyclyl)-pyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors
MXPA04006271A (es) * 2001-12-27 2004-10-04 Theravance Inc Derivados de indolinona utiles como inhibidores de la proteina cinasa.
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20140205537A1 (en) * 2011-06-24 2014-07-24 Zenobia Therapeutics, Inc. Lrrk2 inhibitors
WO2016188421A1 (zh) * 2015-05-25 2016-12-01 中国医学科学院药物研究所 含丙炔酰胺基的2-苯基咪唑类衍生物及其制法和药物组合物与用途
EP3682881A4 (en) 2017-09-14 2021-08-11 Daiichi Sankyo Company, Limited CONNECTION WITH CYCLICAL STRUCTURE
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556672A (en) * 1984-03-19 1985-12-03 Pfizer Inc. 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents
US5086186A (en) * 1989-05-25 1992-02-04 Pfizer Inc. N-trichloroacetyl-2-oxindole-1-carboxamides
US5206261A (en) * 1989-07-25 1993-04-27 Taiho Pharmaceutical Company, Limited Oxindole derivative
WO1991009598A1 (en) * 1990-01-05 1991-07-11 Pfizer Inc. Azaoxindole derivatives
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
WO1992007830A2 (en) * 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
GB9115160D0 (en) * 1991-07-12 1991-08-28 Erba Carlo Spa Methylen-oxindole derivatives and process for their preparation
US5322950A (en) * 1991-12-05 1994-06-21 Warner-Lambert Company Imidazole with angiotensin II antagonist properties
FR2694004B1 (fr) * 1992-07-21 1994-08-26 Adir Nouvelles 3-(Hydroxybenzylidényl)-indoline-2-ones et 3-(hydroxybenzylidényl)-indoline-2-thiones, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent.
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
GB9313638D0 (en) * 1993-07-01 1993-08-18 Erba Carlo Spa Arylidene and heteroarylidene oxindole derivatives and process for their preparation
GB9326136D0 (en) * 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
GB9412719D0 (en) * 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
GB9423997D0 (en) * 1994-11-28 1995-01-11 Erba Carlo Spa Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation
GB9501567D0 (en) * 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
GB9507298D0 (en) * 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
WO1997011692A2 (en) * 1995-09-11 1997-04-03 Osteoarthritis Sciences, Inc. Protein tyrosine kinase inhibitors for treating osteoarthritis
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
GB9610964D0 (en) * 1996-05-24 1996-07-31 Pharmacia & Upjohn Spa Substituted tetralylmethylen-oxindole analogues as tyrosine kinase inhibitors
GB9611797D0 (en) * 1996-06-06 1996-08-07 Pharmacia Spa Substituted quinolylmethylen-oxindole analogues as tyrosine kinase inhibitors
AU4155697A (en) * 1996-08-23 1998-03-06 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
AU7622698A (en) * 1996-12-05 1998-06-29 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
EP0984930B1 (en) * 1997-05-07 2005-04-06 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
WO1999048868A2 (en) * 1998-03-26 1999-09-30 Sugen, Inc. Heterocyclic classes of compounds for the modulating tyrosine protein kinase
SK287132B6 (sk) * 1998-05-29 2009-12-07 Sugen, Inc. Farmaceutická kompozícia obsahujúca pyrolom substituovaný 2-indolinón, súprava obsahujúca uvedenú kompozíciu a použitie pyrolom substituovaného 2-indolinónu
CA2383623A1 (en) * 1998-08-04 2000-02-17 Sugen, Inc. 3-methylidenyl-2-indolinone modulators of protein kinase
US6525072B1 (en) * 1998-08-31 2003-02-25 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
DK1157019T3 (da) * 1998-12-17 2003-07-14 Hoffmann La Roche 4-alkenyl- (og alkynyl-)oxindoler som inhibitorer af cyklinafhængige kinaser, især CDK2

Also Published As

Publication number Publication date
CN1330647A (zh) 2002-01-09
TR200101860T2 (tr) 2001-12-21
US6130239A (en) 2000-10-10
CA2354873A1 (en) 2000-06-22
JP2002532492A (ja) 2002-10-02
TW550262B (en) 2003-09-01
PT1157019E (pt) 2003-06-30
AR024847A1 (es) 2002-10-30
PE20001537A1 (es) 2001-01-09
DE69906152D1 (de) 2003-04-24
EP1157019B1 (en) 2003-03-19
ATE234830T1 (de) 2003-04-15
AU1972700A (en) 2000-07-03
CO5261600A1 (es) 2003-03-31
WO2000035908A1 (en) 2000-06-22
DK1157019T3 (da) 2003-07-14
DE69906152T2 (de) 2004-02-12
BR9916327A (pt) 2001-09-18
EP1157019A1 (en) 2001-11-28
CN1138773C (zh) 2004-02-18
KR20010101274A (ko) 2001-11-14
KR100649925B1 (ko) 2007-02-28
US6252086B1 (en) 2001-06-26
UY25857A1 (es) 2001-07-31
US6303793B1 (en) 2001-10-16
AU770375B2 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
ES2192877T3 (es) 4-alquenil (y alquinil) oxindoles como inhibidores de kinasas ciclina-dependientes, en particular cdk2.
CR20120009A (es) 2-indolinonas sustituidas con pirrolos inhibidores de proteinquinasas (divisional exp. 6728)
AR026036A1 (es) Indolinonas sustituidas en posicion 6, su preparacion y su utilizacion como medicamentos
CR6706A (es) Pirido (2,3-d) pirimidin-2-7-diaminas inhibidores de cinasas
CY1108408T1 (el) Παραγωγα διαζεπινοϊνδολιου ως αναστολεις κινασης
AR028810A1 (es) Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion
ECSP10010034A (es) 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos
ES2171884T3 (es) Compuestos de quinazolina.
PA8550101A1 (es) Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización
PA8537401A1 (es) Diaminotiazoles
ECSP066763A (es) Pirazolopirimidinas novedosas como inhibidores de quinasa ciclina-dependientes
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
UY28526A1 (es) Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
CL2009000780A1 (es) Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k.
UY29300A1 (es) Compuestos quimicos
BR0110371A (pt) Inibidores de delta 3-cinase de fosfatidil-inositol humana
ECSP099821A (es) METABOLITOS DEL INHIBIDOR DE JANUS QUINASA (R)-3-(4-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-3-CICLOPENTILPROPANONITRILO
MY122357A (en) Indolinones having kinase inhibitory activity
ECSP055958A (es) 4-aminopirimidina-5-ona
DOP2004000949A (es) Derivados de pirrolo [3,4-c]pirazol activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que comprenden los mismos
CL2009000241A1 (es) Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
ECSP045473A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
AR070977A2 (es) Compuesto (1r)-1-[({(2r)-2-amino-3-[(8s)-8-(ciclohexilmetil)-2-fenil-5,6-dihidroimidazo[1,2-a]pirazin-7(8h)-il]-3-oxopropil}ditio)metil]-2-[(8s)-8-(ciclohexilmetil)-2-fenil-5,6-dihidroimidazo[1,2-a]pirazin-7(8h)-il]-2-oxoetilamina y sus sales, proceso para su preparacion, composicion farmaceutica y
ECSP11005642A (es) Nuevos pirazolopirimidinas como inhibidores de quinasa dependientes de ciclinas
MX336332B (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.